Instrument Inactif

Communiqués Ceapro Inc. Other OTC

Actions

CRPOF

CA1499071076

Recherche biotechnologique et médicale

Communiqués

03/06/24	Aeterna Zentaris and Ceapro Complete Merger Transaction	GL
03/06/24	Canadian Investment Regulatory Organization Trading Halt - CZO	AQ
29/05/24	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	AQ
29/05/24	Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update	GL
29/04/24	Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	AQ
29/04/24	Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	GL
28/03/24	Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	GL
12/03/24	Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	GL
26/02/24	Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	AQ
26/02/24	Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	GL
23/02/24	Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	GL
15/02/24	Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	GL
14/12/23	Canadian Investment Regulatory Organization Trade Resumption - CZO	AQ
14/12/23	Canadian Investment Regulatory Organization Trading Halt - CZO	AQ
13/12/23	Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	GL
13/12/23	Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	AQ
29/11/23	Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights	GL
27/11/23	Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases	GL
07/11/23	Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology	GL
29/08/23	Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update	GL
29/08/23	Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update	AQ
28/08/23	Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise	AQ
25/08/23	Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise	GL
25/08/23	Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise	AQ
18/07/23	Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	GL